BGT-002 (326E) is an orally active dual ACLY inhibitor and PPARalpha agonist. It reduces lipogenesis by inhibiting synthesis and promoting excretion. BGT-002 has demonstrated efficacy in vivo for improving metabolic dysfunction-associated steatohepatitis (MASH) and alleviating hyperlipidemia. It is applicable for research on hypercholesterolemia and MASH.
Molecular Weight:
326.48
CAS Number:
[2127387-94-2]
Formula:
C19H34O4
Target:
ATP Citrate Lyase|||PPAR
* VAT and and shipping costs not included. Errors and price changes excepted
